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INTRODUCTION 
Since its introduction in 1950 as a systemic 
immunosuppressant (dihydrofolate reductase (DHFR) 
inhibitor), methotrexate (MTX) has been widely used 
In treatment of various malignancies, early ectopic 
pregnancy or chronic inflammatory diseases such as 
some types of carcinoma, rheumatoid arthritis, 
psoriasis etc.1-3 High doses (HD) of MTX (0.5 - 12 g/m2) 
has shown antiproliferative activity and is used in 
treatment of cancer while in low doses,  (LD) MTX (10 
-40mg/m2) has anti-inflammatory and 
immunosuppressive properties while Its long-term use 
is associated with hepatic and pulmonary toxicity.4,5 
 
This case report discusses the Presence of MTX related 
mucositis in a 69 year old gentleman and its 
subsequent treatment leading to complete resolution 
of the lesion.  
 
CASE REPORT 
A 69 year old gentleman visited a dental camp 
complaining of oral ulcers (non-recurrent in nature) 
and dysphagia, who was then referred to a dental clinic 
for proper examination. Medical history of the patient 
revealed that the patient was suffering from 
rheumatoid arthritis, hypertension type II, 
hypothyroidism and chronic obstructive airway 
disease. The medications included tablets Doxofylline 
400 mg BD, Pantoprazole 40 mg OD, Amlodipine 2.5 
mg OD,  Nebivolol 2.5 mg OD, T. Atorvastatin 20 mg 
HS, Clopidogrel 75 mg OD, Levothyroxin 100 mcg OD, 
Methotrexate 7.5 mg HS, and Methylprednisolone 8 
mg OD.  
 
 
 
 
 
Upon further examination, it was revealed that the 
patient was prescribed once weekly dose of  
 
Methotrexate 7.5 mg for his long standing Rheumatoid 
Arthritis,    but    instead   took  MTX   once   daily. No 
medication error or prescription error was seen, and 
rather the daily intake of methotrexate was due to an 
error on the part of the patient itself.  As per Ethical 
considerations, the patient although permitted the 
findings to be published, he, however declined to 
publish his pictures, even though the confidentiality of 
his identity was assured.  
 
Intra-oral clinical examination revealed throat pain, 
dysphagia and non-recurrent oral ulcer. The lips were 
fissured and painfully swollen, erosive ulcers in floor 
of the mouth, buccal and labial mucosa also, the 
patient complained of generalized weakness and 
fatigue. The mucositis was revealed to be grade IV. The 
patient was found to be underweight and 
malnourished.  
 
The clinical picture gave the impression was of oral 
mucositis secondary to methotrexate overdose. 
Treatment was initiated with Inj. Leucovirin Calcium 
40 mg every six hourly for 3 days, Folic acid (Tablet) 5 
mg daily for a week along with intravenous fluids. 
Topical therapy with Choline Salicylate oral gel was 
initiated, Candid mouth wash and Sodium 
Bicarbonate mouth was prescribed along with T. 
Fluconazole, Inj. Mecobalamine. Over time, the 
patient’s  lesions  healed  with  regression of all lesions  
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The prescription of Methotrexate is well-recognized for various neoplastic diseases. For Rheumatoid arthritis, it is prescribed 
once a week, low-dose regimen for the treatment of psoriasis and rheumatoid arthritis. Apart from providing therapeutic benefit, 
it is not devoid of side effects like oral ulceration which may be due to over dosage regarding its once-weekly regime. This case 
report describes a patient with inherent Methotrexate toxicity that developed oral mucositis due to Methotrexate being given for 
rheumatoid arthritis.  
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within few days after starting local and systemic 
therapy. The patient was advised on the dosing pattern 
of MTX and has now been taking MTX on a weekly 
basis with good treatment compliance.  
 
DISCUSSION 
The present case documented toxicity to MTX in the 
form of oral mucositis. As MTX can cause many side 
effects some of which are life threatening, it is of prime 
importance to recognize them as many of these side 
effects can be avoided by a close monitoring and 
adopting good preventive measures.6 
  
Often, oral mucositis can become a dose-limiting 
toxicity and requires the use of opioids for pain relief, 
It also leads to an increased risk of infections, and has 
the potential to cause delays in chemotherapy.7 
Mucositis after MTX is mainly caused by cellular 
damage to rapidly dividing epithelial cells present 
along the entire gastrointestinal tract and it is of 
importance to note that inadequate or delayed 
leucovorin rescue can lead to impaired epithelial cell 
growth and regeneration of the affected cells.8,9,10 
 
The patient, was suffering from Grade IV mucositis, 
which is considered to be an oncologic emergency 
associated with infections, need for parenteral 
nutrition,  increased use of health care resources and 
finances, and even death.8 Therefore the need for an 
increased screening for oral signs and symptoms is 
proposed for patients undergoing systemic 
chemotherapy. Fortunately, the patient described in 
the present case report did fully recover from the 
methotrexate-induced mucositis and did not 
complaint of any oral complications during the last 
follow up.   
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